![]() Europe Syndromic Multiplex Diagnostic Market
The Europe syndromic multiplex diagnostic market is expected to reach USD 2.19 billion by 2032 from USD 1.17 billion in 2024, growing at a CAGR of 8.2% in the forecast period of 2025 to 2032. Mark... もっと見る
※当ページの内容はウェブ更新時の情報です。
SummaryThe Europe syndromic multiplex diagnostic market is expected to reach USD 2.19 billion by 2032 from USD 1.17 billion in 2024, growing at a CAGR of 8.2% in the forecast period of 2025 to 2032.Market Segmentation: Europe Syndromic Multiplex Diagnostic Market, By Product Type (Accessories & Consumables, Instruments, and Software & Services), Infection Type (Viral, Bacterial, Fungal, Parasites, and Others), Disease (Respiratory Infections, Gastroenteritis, Sexually Transmitted Infections, Meningitis, Childhood Infections, Immunosuppression, Tropical Fever, Hepatitis, Eye Infections, and Other Diseases), End User (Hospitals, Clinical Laboratories, Physician Offices, Pharmaceutical & Biotechnology Companies, Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (Germany, U.K., France, Italy, Spain, Russia, Netherlands, Switzerland, Turkey, Belgium, Sweden, Poland, Denmark, Norway, Finland, and Rest of Europe) - Industry Trends & Forecast To 2032 Overview of the Europe Syndromic Multiplex Diagnostic Market Dynamics: Drivers • Rising prevalence of infectious diseases • Rising adoption of molecular diagnostics techniques Restraints • High cost of diagnostic products • Variability in test performance across different manufacturers Opportunities • Advancements in AI & automation • Rising aging population in Europe Market Players: The key market players for Europe Syndromic Multiplex Diagnostic Market are listed below: • F. Hoffmann-La Roche Ltd • DiaSorin S.p.A • BIOMÉRIEUX • Thermo Fisher Scientific Inc. • QIAGEN • BD Veritor (BD) • Bio-Rad Laboratories, Inc. • Danaher Corporation • Seegene Inc. • Hologic, Inc. (U.S.) • Bosch Healthcare Solutions GmbH • Abbott • QuidelOrtho Corporation • Biocartis • PathoFinder Table of ContentsTABLE OF CONTENTS1 INTRODUCTION 34 1.1 OBJECTIVES OF THE STUDY 34 1.2 MARKET DEFINITION 34 1.3 OVERVIEW OF THE EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET 34 1.4 LIMITATIONS 36 1.5 MARKETS COVERED 36 2 MARKET SEGMENTATION 39 2.1 MARKETS COVERED 39 2.2 GEOGRAPHICAL SCOPE 40 2.3 YEARS CONSIDERED FOR THE STUDY 40 2.4 CURRENCY AND PRICING 40 2.5 DBMR TRIPOD DATA VALIDATION MODEL 41 2.6 MULTIVARIATE MODELLING 44 2.7 PRODUCT TYPE LIFELINE CURVE 44 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 45 2.9 DBMR MARKET POSITION GRID 46 2.10 MARKET END USER COVERAGE GRID 47 2.11 VENDOR SHARE ANALYSIS 48 2.12 SECONDARY SOURCES 49 2.13 ASSUMPTIONS 49 3 EXECUTIVE SUMMARY 50 4 PREMIUM INSIGHTS 55 4.1 PESTAL ANALYSIS 56 4.2 PORTERS FIVE FORCES ANALYSIS 57 4.3 INDUSTRY INSIGHTS 58 4.4 TECHNOLOGY ROADMAP 64 5 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: REGULATIONS 67 6 MARKET OVERVIEW 70 6.1 DRIVERS 72 6.1.1 RISING PREVALENCE OF INFECTIOUS DISEASES 72 6.1.2 RISING ADOPTION OF MOLECULAR DIAGNOSTICS TECHNIQUES 73 6.1.3 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS 74 6.1.4 INCREASING DEMAND FOR FAST AND ACCURATE DIAGNOSTIC RESULTS 75 6.2 RESTRAINTS 76 6.2.1 HIGH COST OF DIAGNOSTIC PRODUCTS 76 6.2.2 VARIABILITY IN TEST PERFORMANCE ACROSS DIFFERENT MANUFACTURERS 76 6.3 OPPORTUNITIES 77 6.3.1 ADVANCEMENTS IN AI & AUTOMATION 77 6.3.2 RISING AGING POPULATION IN EUROPE 78 6.3.3 RISING HOSPITAL-ACQUIRED INFECTIONS 79 6.4 CHALLENGES 80 6.4.1 CHALLENGES IN DETECTING RESISTANCE MECHANISMS 80 6.4.2 LACK OF MEDICAL PROFESSIONALS IN EUROPE 81 7 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT TYPE 83 7.1 OVERVIEW 84 7.2 ACCESSORIES & CONSUMABLES 87 7.2.1 PANELS 88 7.2.1.1 MULTIPLEX RESPIRATORY PANELS 89 7.2.1.1.1 MULTIPLEX LOWER RESPIRATORY PANELS 90 7.2.1.1.2 PNEUMONIA (PN)/PNEUMONIA PLUS (PNPLUS) PANELS 91 7.2.1.1.3 UNYVERO LRT TEST 91 7.2.1.1.4 OTHER 91 7.2.1.2 MULTIPLEX UPPER RESPIRATORY PANELS 91 7.2.1.2.1 RESPIRATORY VIRAL PANEL 93 7.2.1.2.2 RESPIRATORY PATHOGEN PANEL (RPP)/RESPIRATORY PANEL 2 (RP2) 93 7.2.1.2.3 RESPIRATORY PANEL EZ (CLIA-WAIVED) 93 7.2.1.2.4 RESPIRATORY PATHOGENS FLEX TEST (RP FLEX) 93 7.2.1.2.5 OTHER PANELS 93 7.2.1.3 MULTIPLEX GI PANELS 93 7.2.1.3.1 GI PATHOGEN PANEL (GPP) 94 7.2.1.3.2 ENTERIC BACTERIAL PANEL 94 7.2.1.3.3 ENTERIC VIRAL PANEL 94 7.2.1.3.4 ENTERIC PARASITE PANEL 94 7.2.1.3.5 EXTENDED ENTERIC BACTERIAL PANEL 94 7.2.1.3.6 OTHER PANELS 94 7.2.1.4 MULTIPLEX BLOOD CULTURE PANELS 95 7.2.1.4.1 BCID PANEL (BROAD-SPECTRUM PATHOGEN IDENTIFICATION) 98 7.2.1.4.2 BCID-GP PANEL (GRAM-POSITIVE BACTERIA PANEL) 98 7.2.1.4.3 BCID-GN PANEL (GRAM-NEGATIVE BACTERIA PANEL) 98 7.2.1.4.4 BCID-FP PANEL (FUNGAL PATHOGEN DETECTION) 98 7.2.1.4.5 GRAM-POSITIVE BLOOD CULTURE TEST (BC-GP) 98 7.2.1.4.6 BLOOD CULTURE TEST (BC-GN) 98 7.2.1.4.7 CANDIDA PANEL 98 7.2.1.4.8 BACTERIA PANEL 98 7.2.1.4.9 PHENOTEST BC 98 7.2.1.4.10 OTHER PANELS 98 7.2.1.5 MENINGITIS/ENCEPHALITIS SYNDROMIC PANEL 98 7.2.1.6 STI TEST PANELS 98 7.2.1.7 OTHER SYNDROMIC MULTIPLEX DIAGNOSTIC PANELS 98 7.3 INSTRUMENTS 99 7.4 SOFTWARE & SERVICES 99 8 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE 100 8.1 OVERVIEW 101 8.2 VIRAL 104 8.2.1 RHINOVIRUS 105 8.2.2 CORONAVIRUS 105 8.2.3 ROTAVIRUS 105 8.2.4 ADENOVIRUS 105 8.2.5 OTHERS 105 8.3 BACTERIAL 105 8.3.1 STAPHYLOCOCCUS 105 8.3.2 PNEUMONIA 105 8.3.3 BORDETELLA PERTUSSIS 105 8.3.4 OTHERS 105 8.4 FUNGAL 105 8.5 PARASITES 106 8.6 OTHERS 106 9 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE 107 9.1 OVERVIEW 108 9.2 RESPIRATORY INFECTIONS 112 9.3 GASTROENTERITIS 112 9.4 SEXUALLY TRANSMITTED INFECTIONS 112 9.5 MENINGITIS 113 9.6 CHILDHOOD INFECTIONS 113 9.7 IMMUNOSUPPRESSION 113 9.8 TROPICAL FEVER 113 9.9 HEPATITIS 113 9.10 EYE INFECTIONS 113 9.11 OTHER DISEASES 113 10 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER 114 10.1 OVERVIEW 115 10.2 HOSPITALS 119 10.2.1 BY TYPE, 119 10.2.1.1 PRIVATE 119 10.2.1.2 PUBLIC 119 10.2.2 BY LEVEL 120 10.2.2.1 TIER 1 120 10.2.2.2 TIER 2 120 10.2.2.3 TIER 3 120 10.3 CLINICAL LABORATORIES 121 10.3.1 BY TYPE 121 10.3.1.1 PRIVATE 121 10.3.1.2 PUBLIC 121 10.4 PHYSICIAN OFFICES 121 10.5 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 121 10.6 RESEARCH INSTITUTES 121 10.7 OTHERS 121 11 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL 122 11.1 OVERVIEW 123 11.2 DIRECT TENDER 126 11.3 RETAIL SALES 126 11.3.1 ONLINE 126 11.3.2 OFFLINE 126 11.4 OTHERS 127 12 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY COUNTRIES 128 12.1 EUROPE 128 12.1.1 GERMANY 131 12.1.2 U.K. 142 12.1.3 FRANCE 153 12.1.4 ITALY 164 12.1.5 SPAIN 174 12.1.6 RUSSIA 184 12.1.7 NETHERLANDS 194 12.1.8 TURKEY 213 12.1.9 BELGIUM 223 12.1.10 SWEDEN 233 12.1.11 POLAND 243 12.1.12 DENMARK 253 12.1.13 NORWAY 263 12.1.14 FINLAND 274 12.1.15 REST OF EUROPE 284 13 EUROPE SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY LANDSCAPE 285 13.1 COMPANY SHARE ANALYSIS: EUROPE 285 14 SWOT ANALYSIS 286 15 COMPANY PROFILES 287 15.1 F. HOFFMANN-LA ROCHE LTD 287 15.1.1 COMPANY SNAPSHOT 287 15.1.2 REVENUE ANALYSIS 288 15.1.3 PRODUCT PORTFOLIO 288 15.1.4 RECENT DEVELOPMENTS 289 15.2 DIASORIN S.P.A 290 15.2.1 COMPANY SNAPSHOT 290 15.2.2 REVENUE ANALYSIS 290 15.2.3 SOULUTION PORTFOLIO 291 15.2.4 RECENT DEVELOPMENT 292 15.3 BIOMERIEUX 293 15.3.1 COMPANY SNAPSHOT 293 15.3.2 REVENUE ANALYSIS 293 15.3.3 PRODUCT PORTFOLIO 294 15.3.4 RECENT DEVELOPMENTS/NEWS 295 15.4 THERMO FISHER SCIENTIFIC INC. 297 15.4.1 COMPANY SNAPSHOT 297 15.4.2 REVENUE ANALYSIS 297 15.4.3 PRODUCT PORTFOLIO 298 15.4.4 RECENT DEVELOPMENTS 301 15.5 QIAGEN 302 15.5.1 COMPANY SNAPSHOT 302 15.5.2 REVENUE ANALYSIS 302 15.5.3 PRODUCT PORTFOLIO 303 15.5.4 RECENT DEVELOPMENTS 308 15.6 ABBOTT 309 15.6.1 COMPANY SNAPSHOT 309 15.6.2 REVENUE ANALYSIS 309 15.6.3 PRODUCT PORTFOLIO 310 15.6.4 RECENT DEVELOPMENTS/NEWS 310 15.7 BD VERITOR (BD) 312 15.7.1 COMPANY SNAPSHOT 312 15.7.2 REVENUE ANALYSIS 312 15.7.3 PRODUCT PORTFOLIO 313 15.7.4 RECENT DEVELOPMENTS 314 15.8 BIOCARTIS 315 15.8.1 COMPANY SNAPSHOT 315 15.8.2 PRODUCT PORTFOLIO 315 15.8.3 RECENT DEVELOPMENT 315 15.9 BIO-RAD LABORATORIES, INC. 316 15.9.1 COMPANY SNAPSHOT 316 15.9.2 REVENUE ANALYSIS 317 15.9.3 PRODUCT PORTFOLIO 317 15.9.4 RECENT DEVELOPMENT 318 15.10 BOSCH HEALTHCARE SOLUTIONS GMBH 319 15.10.1 COMPANY SNAPSHOT 319 15.10.2 PRODUCT PORTFOLIO 319 15.10.3 RECENT DEVELOPMENT 328 15.11 DANAHER CORPORATION 329 15.11.1 COMPANY SNAPSHOT 329 15.11.2 REVENUE ANALYSIS 329 15.11.3 PRODUCT PORTFOLIO 330 15.11.4 RECENT DEVELOPMENT 330 15.12 HOLOGIC, INC. 331 15.12.1 COMPANY SNAPSHOT 331 15.12.2 REVENUE ANALYSIS 331 15.12.3 PRODUCT PORTFOLIO 332 15.12.4 RECENT DEVELOPMENTS/NEWS 333 15.13 PATHOFINDER 334 15.13.1 COMPANY SNAPSHOT 334 15.13.2 PRODUCT PORTFOLIO 334 15.13.3 RECENT DEVELOPMENT 334 15.14 QUIDELORTHO CORPORATION 335 15.14.1 COMPANY SNAPSHOT 335 15.14.2 REVENUE ANALYSIS 335 15.14.3 PRODUCT PORTFOLIO 336 15.14.4 RECENT DEVELOPMENTS/NEWS 337 15.15 SEEGENE INC. 339 15.15.1 COMPANY SNAPSHOT 339 15.15.2 PRODUCT PORTFOLIO 339 15.15.3 RECENT DEVELOPMENTS 343 16 QUESTIONNAIRE 344 17 RELATED REPORTS 348
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療機器)の最新刊レポート
Data Bridge Market Research社の 医療デバイス分野 での最新刊レポート
本レポートと同じKEY WORD(diagnostic)の最新刊レポート
よくあるご質問Data Bridge Market Research社はどのような調査会社ですか?データブリッジマーケットリサーチ(Data Bridge Market Research)は500名以上の多様な分野のアナリストが所属するインドの調査会社です。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|